Toggle Main Menu Toggle Search

Open Access padlockePrints

Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics

Lookup NU author(s): Dr Stephen Thompson, John Dessi, Emeritus Professor Colin Self

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The administration of anti-CD3 antibodies, either unmodified or in bispecific formats, has been shown to kill tumors. However, their activity needs to be carefully controlled. We have approached this problem by inhibiting their anti-CD3 activity until it is required. Folated anti-human CD3 antibody bispecific conjugates were therefore synthesised in which the folate portion of the conjugates remained free to bind to folate receptor (FR) expressing cancer cells, whilst their anti-CD3 activity was reversibly inhibited. On irradiation with UV-A light, the T-cell binding activity of the anti-CD3 antibody can be restored only when and where it is required, i.e., adjacent to a tumor. Conjugate bound to FR expressed on normal tissues in other parts of the body remains inactive. This report describes the preclinical in vivo testing of these conjugates in transgenic mice whose T-cells express human CD3 molecules. When the 'cloaked' conjugates were reactivated in the region of the primary tumor, both primary tumor growth and liver metastasis were markedly reduced. That the deliberate targeting of T-cell activity locally to the primary tumor also resulted in reduced distant metastatic growth was a key finding. Light-activatable bispecific antibody conjugates similar to those described here offer a means to control T-cell targeting with a much higher degree of specificity to tumors because they minimize potentially dangerous and unwanted side effects in non-illuminated areas. The addition of light-specific targeting to the inherent tumor specific targeting of therapeutic antibody conjugates could result in the development of safer treatments for patients.


Publication metadata

Author(s): Thompson S, Dessi J, Self CH

Publication type: Article

Publication status: Published

Journal: MAbs

Year: 2009

Volume: 1

Issue: 4

Pages: 348-356

ISSN (print): 1942-0862

ISSN (electronic): 1942-0870

Publisher: Landes Bioscience

URL: http://dx.doi.org/10.4161/mabs.1.4.9045

DOI: 10.4161/mabs.1.4.9045


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share